<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="tca70071" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Thorac Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Thorac Cancer</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1759-7714</journal-id><journal-id journal-id-type="publisher-id">TCA</journal-id><journal-title-group><journal-title>Thoracic Cancer</journal-title></journal-title-group><issn pub-type="ppub">1759-7706</issn><issn pub-type="epub">1759-7714</issn><publisher><publisher-name>John Wiley &#x00026; Sons Australia, Ltd</publisher-name><publisher-loc>Melbourne</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40396214</article-id><article-id pub-id-type="pmc">PMC12093106</article-id>
<article-id pub-id-type="doi">10.1111/1759-7714.70071</article-id><article-id pub-id-type="publisher-id">TCA70071</article-id><article-id pub-id-type="other">TCA-OA-12-2024-12106.R3</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Anlotinib Plus Osimertinib in Osimertinib&#x02010;Resistant Nonsquamous Nonsmall Cell Lung Cancer With Gradual Progression: A Retrospective Study</article-title></title-group><contrib-group><contrib id="tca70071-cr-0001" contrib-type="author"><name><surname>Hua</surname><given-names>Yu</given-names></name><xref rid="tca70071-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="tca70071-cr-0002" contrib-type="author"><name><surname>Liu</surname><given-names>Minghui</given-names></name><xref rid="tca70071-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="tca70071-cr-0003" contrib-type="author"><name><surname>Li</surname><given-names>Boshi</given-names></name><xref rid="tca70071-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="tca70071-cr-0004" contrib-type="author"><name><surname>Zhang</surname><given-names>Hongbing</given-names></name><xref rid="tca70071-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="tca70071-cr-0005" contrib-type="author"><name><surname>Zhang</surname><given-names>Zihe</given-names></name><xref rid="tca70071-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="tca70071-cr-0006" contrib-type="author"><name><surname>Wang</surname><given-names>Yanan</given-names></name><xref rid="tca70071-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="tca70071-cr-0007" contrib-type="author"><name><surname>Liu</surname><given-names>Jinghao</given-names></name><xref rid="tca70071-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="tca70071-cr-0008" contrib-type="author"><name><surname>Li</surname><given-names>Xin</given-names></name><xref rid="tca70071-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="tca70071-cr-0009" contrib-type="author"><name><surname>Li</surname><given-names>Yongwen</given-names></name><xref rid="tca70071-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="tca70071-cr-0010" contrib-type="author"><name><surname>Wei</surname><given-names>Sen</given-names></name><xref rid="tca70071-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="tca70071-cr-0011" contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Hongyu</given-names></name><xref rid="tca70071-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>liuhongyu123@hotmail.com</email></address></contrib><contrib id="tca70071-cr-0012" contrib-type="author" corresp="yes"><name><surname>Chen</surname><given-names>Jun</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2362-5359</contrib-id><xref rid="tca70071-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="tca70071-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>hunterchenjun@hotmail.com</email></address></contrib></contrib-group><aff id="tca70071-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Lung Cancer Surgery</named-content>
<institution>Tianjin Medical University General Hospital</institution>
<city>Tianjin</city>
<country country="CN">China</country>
</aff><aff id="tca70071-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment</named-content>
<institution>Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital</institution>
<city>Tianjin</city>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Hongyu Liu (<email>liuhongyu123@hotmail.com</email>)<break/>
Jun Chen (<email>hunterchenjun@hotmail.com</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><volume>16</volume><issue seq="80">10</issue><issue-id pub-id-type="doi">10.1111/tca.v16.10</issue-id><elocation-id>e70071</elocation-id><history>
<date date-type="rev-recd"><day>31</day><month>3</month><year>2025</year></date>
<date date-type="received"><day>10</day><month>12</month><year>2024</year></date>
<date date-type="accepted"><day>10</day><month>4</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Australia, Ltd--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Thoracic Cancer</italic> published by John Wiley &#x00026; Sons Australia, Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:TCA-16-e70071.pdf"/><abstract><title>ABSTRACT</title><sec id="tca70071-sec-0001"><title>Background</title><p>Previous studies have shown that anlotinib plus third&#x02010;generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR&#x02010;TKIs) overcome acquired resistance to EGFR&#x02010;TKIs in patients with advanced EGFR&#x02010;mutant nonsmall cell lung cancer (NSCLC). This study aimed to retrospectively evaluate whether anlotinib plus osimertinib overcame acquired resistance in patients with nsq&#x02010;NSCLC who gradually progressed after first&#x02010;line EGFR&#x02010;TKI treatment.</p></sec><sec id="tca70071-sec-0002"><title>Methods</title><p>This study included patients with nsq&#x02010;NSCLC who developed gradual progression after first&#x02010;line osimertinib treatment, underwent an anlotinib plus osimertinib regimen in Tianjin Medical University General Hospital, and had available data from October 8, 2020 to October 14, 2023. Outcomes included the efficacy, assessed by progression&#x02010;free survival (PFS), of anlotinib plus osimertinib treatment (PFS1) and prior osimertinib treatment (PFS2), to disease progression, objective response rate (ORR), disease control rate (DCR), and safety as assessed by the incidence of treatment&#x02010;related toxicities.</p></sec><sec id="tca70071-sec-0003"><title>Results</title><p>A total of 28 patients with nsq&#x02010;NSCLC were included, with a median follow&#x02010;up of 12&#x02009;months (range, 7.8&#x02013;16.2). Treatment with anlotinib plus osimertinib led to a median PFS1 of 10.0&#x02009;months (95% confidence interval [CI], 8.4&#x02013;11.6). With a median follow&#x02010;up from prior osimertinib therapy of 31.5&#x02009;months (range, 20.8&#x02013;42.2), the median PFS2 was 22.0&#x02009;months (95% CI, 17.5&#x02013;26.5). The ORR to combination therapy was 3.6% (95% CI, 0.2&#x02013;20.2) and the DCR was 85.7% (95% CI, 67.3&#x02013;96.0). All patients experienced treatment&#x02010;related toxicities, with 10.7% showing grade 3, and none were grade &#x02265;&#x02009;4.</p></sec><sec id="tca70071-sec-0004"><title>Conclusions</title><p>Anlotinib plus osimertinib exhibited encouraginsg anti&#x02010;tumor activity and had a manageable safety profile in patients with nsq&#x02010;NSCLC showing gradual progression on osimertinib.</p></sec></abstract><abstract abstract-type="graphical"><p>Previous studies have shown that anlotinib plus third&#x02010;generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR&#x02010;TKIs) overcome acquired resistance to EGFR&#x02010;TKIs in patients with advanced EGFR&#x02010;mutant nonsmall cell lung cancer (NSCLC). This study included patients with nsq&#x02010;NSCLC who developed gradual progression after first&#x02010;line osimertinib treatment and underwent anlotinib plus osimertinib. A total of 28 patients with nsq&#x02010;NSCLC were included, with a median follow&#x02010;up of 12&#x02009;months (range, 7.8&#x02013;16.2). Treatment with anlotinib plus osimertinib led to a median PFS1 of 10.0&#x02009;months. With a median follow&#x02010;up from prior osimertinib therapy of 31.5&#x02009;months, the median PFS2 was 22.0&#x02009;months. The ORR to combination therapy was 3.6% and the DCR was 85.7%. All patients experienced treatment&#x02010;related toxicities, with 10.7% showing grade 3 and none were grade &#x02265;&#x02009;4. Anlotinib plus osimertinib exhibited encouraging anti&#x02010;tumor activity and had a manageable safety profile in patients with nsq&#x02010;NSCLC showing gradual progression on osimertinib.<boxed-text position="anchor" content-type="graphic" id="tca70071-blkfxd-0001"><graphic xlink:href="TCA-16-e70071-g001.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="tca70071-kwd-0001">anlotinib</kwd><kwd id="tca70071-kwd-0002">nonsquamous nonsmall cell lung cancer</kwd><kwd id="tca70071-kwd-0003">osimertinib</kwd><kwd id="tca70071-kwd-0004">resistance</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>National Natural Science Foundation of China
</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id>82072595</award-id><award-id>81773207</award-id><award-id>82172569</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Natural Science Foundation of Tianjin Municipality
</institution><institution-id institution-id-type="doi">10.13039/501100006606</institution-id></institution-wrap></funding-source><award-id>23JCZDJC00710</award-id><award-id>23JCYBJC01010</award-id></award-group></funding-group><counts><fig-count count="4"/><table-count count="3"/><page-count count="9"/><word-count count="5800"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:21.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="tca70071-ntgp-0001"><fn fn-type="funding" id="tca70071-note-0001"><p>
<bold>Funding:</bold> This work was supported by National Natural Science Foundation of China (82072595, 81773207, and 82172569), and Natural Science Foundation of Tianjin Municipality (23JCZDJC00710, 23JCYBJC01010).</p></fn><fn fn-type="equal" id="tca70071-note-0002"><p>Yu Hua, Minghui Liu, and Boshi Li have contributed equally to this work and share first authorship.</p></fn></fn-group></notes></front><body id="tca70071-body-0001"><sec id="tca70071-sec-0005"><label>1</label><title>Introduction</title><p>Nonsmall cell lung cancer (NSCLC) is the most prevalent histological type of lung cancer, representing over 80% of all cases&#x000a0;[<xref rid="tca70071-bib-0001" ref-type="bibr">1</xref>, <xref rid="tca70071-bib-0002" ref-type="bibr">2</xref>] of which more than half are classified as nonsquamous (nsq)&#x02010;NSCLC [<xref rid="tca70071-bib-0003" ref-type="bibr">3</xref>, <xref rid="tca70071-bib-0004" ref-type="bibr">4</xref>]. Most patients are diagnosed at an advanced stage and have a poor prognosis. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR&#x02010;TKIs) have become the first&#x02010;line treatment of choice for patients with NSCLC harboring EGFR&#x02010;sensitizing mutations. While EGFR&#x02010;TKIs initially improved the prognosis and quality of life of patients, overall cure and survival rates remain low due to inevitably acquired resistance [<xref rid="tca70071-bib-0005" ref-type="bibr">5</xref>, <xref rid="tca70071-bib-0006" ref-type="bibr">6</xref>]. Patients tend to experience disease progression around 9&#x02013;13&#x02009;months after receiving treatment with first&#x02010;generation EGFR&#x02010;TKIs [<xref rid="tca70071-bib-0007" ref-type="bibr">7</xref>].</p><p>Osimertinib is an irreversible third&#x02010;generation EGFR&#x02010;TKI that can overcome EGFR T790M mutation&#x02013;mediated resistance. It has shown better efficacy and safety than first&#x02010;generation EGFR&#x02010;TKIs for patients with EGFR&#x02010;mutant NSCLC in a first&#x02010;line setting [<xref rid="tca70071-bib-0008" ref-type="bibr">8</xref>]. Therefore, osimertinib has become the main treatment for EGFR&#x02010;mutated NSCLC, in both first&#x02010; and second&#x02010;line settings [<xref rid="tca70071-bib-0009" ref-type="bibr">9</xref>, <xref rid="tca70071-bib-0010" ref-type="bibr">10</xref>]. However, previous studies have indicated that subsequent clinical progression after treatment with osimertinib is inevitable and remains a major therapeutic challenge [<xref rid="tca70071-bib-0011" ref-type="bibr">11</xref>, <xref rid="tca70071-bib-0012" ref-type="bibr">12</xref>, <xref rid="tca70071-bib-0013" ref-type="bibr">13</xref>, <xref rid="tca70071-bib-0014" ref-type="bibr">14</xref>]. The majority of patients choose to receive traditional chemotherapy as the main subsequent treatment after progression. However, only limited benefits are obtained, with a post&#x02010;progression survival of 7.8&#x02009;months [<xref rid="tca70071-bib-0015" ref-type="bibr">15</xref>], leaving a huge demand for novel strategies.</p><p>Anti&#x02010;angiogenic drugs stop or slow NSCLC progression by targeting angiogenic signaling pathways and blocking the formation of new blood vessels necessary for tumor growth [<xref rid="tca70071-bib-0016" ref-type="bibr">16</xref>]. To put off or overcome any acquired resistance to osimertinib, combinations of anti&#x02010;angiogenic drugs with osimertinib have been tried in clinical trials. However, prospective studies have unfortunately failed to show an obvious survival benefit in using osimertinib plus several anti&#x02010;angiogenic drugs (bevacizumab, ramucirumab) [<xref rid="tca70071-bib-0017" ref-type="bibr">17</xref>, <xref rid="tca70071-bib-0018" ref-type="bibr">18</xref>, <xref rid="tca70071-bib-0019" ref-type="bibr">19</xref>]. Due to the heterogeneity of lung cancer and according to the nature of progression after EGFR&#x02010;TKI resistance, it is divided into three clinical modes: dramatic, gradual, and local progressions [<xref rid="tca70071-bib-0020" ref-type="bibr">20</xref>]. Of these, the gradual progression group showed a relatively better clinical benefit [<xref rid="tca70071-bib-0021" ref-type="bibr">21</xref>]. Therefore, researchers have begun to further explore the efficacy of EGFR&#x02010;TKI plus anti&#x02010;angiogenic drug regimens in this subgroup in order to provide a more effective and safer treatment option for this population [<xref rid="tca70071-bib-0022" ref-type="bibr">22</xref>, <xref rid="tca70071-bib-0023" ref-type="bibr">23</xref>]. Most studies of such combination therapies for this special group of patients have been retrospective, and high&#x02010;level evidence published to prove efficacy is still lacking. Anlotinib, a multitargeted small&#x02010;molecule TKI, effectively combats tumor angiogenesis and inhibits tumor growth by inhibiting vascular endothelial growth factor receptor, platelet&#x02010;derived growth factor receptor, fibroblast growth factor receptor, and c&#x02010;Kit signaling pathways. Based on its anti&#x02010;angiogenic activity and anti&#x02010;tumor efficacy, anlotinib has been approved for the treatment of advanced NSCLC [<xref rid="tca70071-bib-0024" ref-type="bibr">24</xref>]. In addition, prior studies have shown that anlotinib plus other EGFR&#x02010;TKIs (gefitinib, afatinib) overcome acquired resistance to EGFR&#x02010;TKI in patients with advanced EGFR&#x02010;mutant NSCLC [<xref rid="tca70071-bib-0025" ref-type="bibr">25</xref>, <xref rid="tca70071-bib-0026" ref-type="bibr">26</xref>]. However, evidence is lacking on the effectiveness of combining anlotinib with osimertinib in patients experiencing gradual progression following initial osimertinib treatment.</p><p>Therefore, in this retrospective study, we comprehensively report on the efficacy and safety of combining anlotinib with osimertinib in patients with nsq&#x02010;NSCLC who developed resistance and progressed gradually after initial treatment with osimertinib. We present this article in accordance with the STROBE reporting checklist.</p></sec><sec sec-type="methods" id="tca70071-sec-0006"><label>2</label><title>Methods</title><sec id="tca70071-sec-0007"><label>2.1</label><title>Study Design and Patients</title><p>This observational, retrospective study was conducted in the Department of Lung Cancer Surgery, Tianjin Medical University General Hospital (Tianjin, China). Patients with nsq&#x02010;NSCLC who showed gradual progression after osimertinib and who received anlotinib plus osimertinib from October 8, 2020 to October 14, 2023, were consecutively included. The study was approved by the Ethics Committee of Tianjin Medical University General Hospital (approval number: IRB2023&#x02010;YX&#x02010;324&#x02010;01). It was conducted in compliance with the 1964 Declaration of Helsinki and applicable local laws and regulations.</p><p>Patient inclusion criteria were: (1) aged &#x02265;&#x02009;18&#x02009;years; (2) had histologically or cytologically confirmed unresectable, stage III or IV nsq&#x02010;NSCLC; (3) had at least one radiologically measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1); (4) had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of &#x02264;&#x02009;2; (5) had an activated EGFR mutation (L858R, T790M or 19DEL); (6) had a life expectancy of &#x02265;&#x02009;3&#x02009;months; and (7) showed gradual progression after first&#x02010;line treatment with osimertinib. Gradual progression was defined as disease control &#x02265;&#x02009;6&#x02009;months, no significant increment of tumor burden, progressive involvement of nontarget lesions with a score &#x02264;&#x02009;2 compared with the previous evaluation, and a symptom score &#x02264;&#x02009;1 [<xref rid="tca70071-bib-0019" ref-type="bibr">19</xref>].</p><p>Exclusion criteria included: (1) had small cell lung cancer (including mixed small cell and NSCLC) or lung squamous cell carcinoma; (2) had an ECOG PS of &#x0003e;&#x02009;2; (3) had contraindications to Anlotini, including uncontrolled hypertension, recent myocardial infarction, congestive heart failure, a high risk of active bleeding (e.g., gastrointestinal hemorrhage, coagulopathy), uncontrolled central nervous system metastases, or severe hypersensitivity reactions to anlotinib and its excipients; and (4) had dramatic progression after first&#x02010;line treatment with osimertinib. Dramatic progression was defined as disease control &#x02265;&#x02009;3&#x02009;months, rapid progression of multiple target lesions or progressive involvement of nontarget lesions with a score &#x0003e;&#x02009;2 compared with a previous evaluation, and a symptom score &#x0003e;&#x02009;1 [<xref rid="tca70071-bib-0019" ref-type="bibr">19</xref>].</p></sec><sec id="tca70071-sec-0008"><label>2.2</label><title>Therapy and Data Collection</title><p>All patients had received 8&#x02009;mg anlotinib plus 80&#x02009;mg osimertinib orally once daily in a 3&#x02010;week treatment cycle, with 2 consecutive weeks of treatment and 1&#x02009;week of rest, until disease progression. Dose adjustment was performed according to drug instructions. When grade 3 hematologic toxicity or grade 2 or higher nonhematologic toxicity occurred, treatment was temporarily suspended and symptomatic treatment was given at the discretion of the physician until toxicity decreased to &#x02264; grade 1.</p><p>Patients' demographic and clinical characteristics (e.g., age, gender, smoking status, original EGFR mutation types, clinical stage, carcinoembryonic antigen [CEA] levels, metastasis, tumor diameter, and ECOG PS), tumor response data, survival status, and safety were collected retrospectively. All data were obtained from electronic medical records and follow&#x02010;up visits made by telephone. Patients' records were manually reviewed to confirm drug administration and the documentation of adverse events. Data were then pooled into a single secure database.</p></sec><sec id="tca70071-sec-0009"><label>2.3</label><title>Outcomes</title><p>Efficacy outcomes were: progression&#x02010;free survival (PFS) of combination therapy (PFS1; defined as the time from starting anlotinib plus osimertinib treatment to the date of disease progression on combination therapy from any cause); PFS2 (defined as the time from prior osimertinib to the date of disease progression on combination therapy from any cause); and objective response rate (ORR) and disease control rate (DCR) after combination therapy per RECIST v1.1. The ORR was defined as the proportion of patients showing a complete response (CR) or partial response (PR) in two consecutive assessments collected at least 4&#x02009;weeks apart. The DCR was defined as the proportion of patients showing a CR, PR, or stable disease (SD). Tumor response was assessed by physicians using low&#x02010;dose spiral computed tomography according to RECIST v1.1. Safety was assessed by treatment&#x02010;related toxicities recorded during combination therapy. Toxicity was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).</p></sec><sec id="tca70071-sec-0010"><label>2.4</label><title>Statistical Analysis</title><p>Statistical analysis was performed using SPSS 25.0 (IBM Corporation, Armonk, NY, USA) and GraphPad Prism 9 (GraphPad Software, La Jolla, CA, USA). Demographic and clinical characteristics were summarized descriptively as a median (range) for continuous variables and as a number (%) for categorical variables. Survival data were estimated using the Kaplan&#x02013;Meier method with corresponding two&#x02010;sided 95% confidence intervals (CIs). For survival analysis, patients without disease progression or death were censored at the date of the last follow&#x02010;up. A log&#x02010;rank test was applied to compare PFS between subgroups. Hazard ratios and corresponding 95% CIs were estimated from a Cox model. Response data (ORR and DCR) were calculated using a Clopper&#x02013;Pearson method and compared with Fisher's precision probability test for subgroup analysis. Corresponding 95% CIs were calculated using a normal approximation to the binomial distribution. A two&#x02010;tailed test with a significance level of <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant (unless otherwise stated).</p></sec></sec><sec sec-type="results" id="tca70071-sec-0011"><label>3</label><title>Results</title><sec id="tca70071-sec-0012"><label>3.1</label><title>Patient Characteristics</title><p>Between October 8, 2020 and October 14, 2023, a total of 28 patients (12 males) were included in this study (Figure&#x000a0;<xref rid="tca70071-fig-0001" ref-type="fig">1</xref>), and all patients underwent tumor biopsy as part of their clinical evaluation. The 28 patients had a median age of 67&#x02009;years (range, 40&#x02013;80&#x02009;years; Table&#x000a0;<xref rid="tca70071-tbl-0001" ref-type="table">1</xref>). All patients (100%) had a pathological type of lung adenocarcinoma. Most patients were nonsmokers (60.7%) and were clinical stage IV (53.6%) and ECOG PS &#x02264;&#x02009;1 (75.0%). Regarding EGFR mutation type, 14 (50%) patients had an exon 21 L858R mutation, nine (32.1%) had a T790M mutation, and five (17.9%) had an exon 19 deletion (19Del). Additionally, the co&#x02010;existence of EGFR and other mutations was detected in 13 (46.4%) patients. Brain metastases occurred in nine (32.1%) patients.</p><fig position="float" fig-type="FIGURE" id="tca70071-fig-0001"><label>FIGURE 1</label><caption><p>Flow of patients.</p></caption><graphic xlink:href="TCA-16-e70071-g004" position="anchor" id="jats-graphic-3"/></fig><table-wrap position="float" id="tca70071-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Patient characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="bottom" rowspan="1" colspan="1">Patients (<italic toggle="yes">n</italic>&#x02009;=&#x02009;28)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="2" valign="top" rowspan="1">Age, years</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median</td><td align="center" valign="top" rowspan="1" colspan="1">67 (40&#x02013;80)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;60</td><td align="center" valign="top" rowspan="1" colspan="1">4 (14.3)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x02265;&#x02009;60</td><td align="center" valign="top" rowspan="1" colspan="1">24 (85.7)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Pathological type</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lung adenocarcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">28 (100)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Sex</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">12 (42.9)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">16 (57.1)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">ECOG PS</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">0&#x02013;1</td><td align="center" valign="top" rowspan="1" colspan="1">21 (75.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">7 (25.0)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Smoking status</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Smoker</td><td align="center" valign="top" rowspan="1" colspan="1">11 (39.3)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Nonsmoker</td><td align="center" valign="top" rowspan="1" colspan="1">17 (60.7)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Original EGFR mutation types</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">L858R</td><td align="center" valign="top" rowspan="1" colspan="1">14 (50.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">T790M</td><td align="center" valign="top" rowspan="1" colspan="1">9 (32.1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">19Del</td><td align="center" valign="top" rowspan="1" colspan="1">5 (17.9)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Concomitant mutations</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">TP53</td><td align="center" valign="top" rowspan="1" colspan="1">5 (17.9)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other mutations</td><td align="center" valign="top" rowspan="1" colspan="1">8 (28.6)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Clinical stage</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">III</td><td align="center" valign="top" rowspan="1" colspan="1">13 (46.4)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">IV</td><td align="center" valign="top" rowspan="1" colspan="1">15 (53.6)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Brain metastasis</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">9 (32.1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">19 (67.9)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">CEA</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;5</td><td align="center" valign="top" rowspan="1" colspan="1">2 (7.1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x02265;&#x02009;5</td><td align="center" valign="top" rowspan="1" colspan="1">26 (92.9)</td></tr><tr><td align="left" colspan="2" valign="top" rowspan="1">Tumor diameter</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x02264;&#x02009;3</td><td align="center" valign="top" rowspan="1" colspan="1">11 (39.3)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">3&#x02013;5</td><td align="center" valign="top" rowspan="1" colspan="1">14 (50.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x0003e;&#x02009;5</td><td align="center" valign="top" rowspan="1" colspan="1">3 (10.7)</td></tr></tbody></table><table-wrap-foot id="tca70071-ntgp-0002"><fn id="tca70071-note-0003"><p>
<italic toggle="yes">Note:</italic> Data are median (range) and <italic toggle="yes">n</italic> (%).</p></fn><fn id="tca70071-note-0004"><p>Abbreviations: CEA, carcinoembryonic antigen; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor.</p></fn></table-wrap-foot></table-wrap></sec><sec id="tca70071-sec-0013"><label>3.2</label><title>Tumor Response</title><p>The post&#x02010;treatment response was evaluated for all 28 included patients, being evaluable for efficacy analysis. One (3.6%) patient achieved a PR after combination therapy (Table&#x000a0;<xref rid="tca70071-tbl-0002" ref-type="table">2</xref>), resulting in an ORR of 3.6% (95% CI, 0.2&#x02013;20.2). An additional 23 (82.1%) patients showed SD as the best response. Thus, the DCR was 85.7% (95% CI, 67.3&#x02013;96.0; Figure&#x000a0;<xref rid="tca70071-fig-0002" ref-type="fig">2A</xref> and Table&#x000a0;<xref rid="tca70071-tbl-0002" ref-type="table">2</xref>). The time period of treatment for all patients is shown in Figure&#x000a0;<xref rid="tca70071-fig-0002" ref-type="fig">2B</xref>. As for the data cut&#x02010;off, out of the 28 patients who received anlotinib plus osimertinib treatment, 24 (85.7%) patients had their tumor progression controlled, four (14.3%) patients discontinued combination treatment due to disease progression, and 14 (50%) patients discontinued combination therapy for various reasons. Durable responses for over 6&#x02009;months were observed in 22 (78.6%) patients and responses were ongoing in 10 (35.7%) patients. The longest duration of response was 17&#x02009;months and was observed in one patient with an EGFR T790M/ERBB2 mutation.</p><table-wrap position="float" id="tca70071-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Clinical response to anlotinib plus osimertinib in nsq&#x02010;NSCLC patients with gradual progression on osimertinib.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Efficacy evaluation</th><th align="center" valign="bottom" rowspan="1" colspan="1">Patients (<italic toggle="yes">n</italic>&#x02009;=&#x02009;28)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="2" valign="top" rowspan="1">Best response, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">PR</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.6)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">SD</td><td align="center" valign="top" rowspan="1" colspan="1">23 (82.1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">PD</td><td align="center" valign="top" rowspan="1" colspan="1">4 (14.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ORR, % (95% CI)</td><td align="center" valign="top" rowspan="1" colspan="1">3.6 (0.2&#x02013;20.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DCR, % (95% CI)</td><td align="center" valign="top" rowspan="1" colspan="1">85.7 (67.3&#x02013;96.0)</td></tr></tbody></table><table-wrap-foot id="tca70071-ntgp-0003"><fn id="tca70071-note-0005"><p>
<italic toggle="yes">Note:</italic> Data are <italic toggle="yes">n</italic> (%), % (95% CI), or median (95% CI).</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="tca70071-fig-0002"><label>FIGURE 2</label><caption><p>Tumor responses. (A) Maximum change from baseline in the sum of diameters of target lesions. (B) Swimmer plot of time on treatment.</p></caption><graphic xlink:href="TCA-16-e70071-g002" position="anchor" id="jats-graphic-5"/></fig><p>In a subgroup analysis of tumor response, no significant association was found between DCR and baseline characteristics, including age, gender, EGFR mutation types, smoking status, concomitant mutations, brain organ metastasis, CEA levels, and tumor diameter (Figure&#x000a0;<xref rid="tca70071-supitem-0001" ref-type="supplementary-material">S1</xref>). Stage IV patients demonstrated a significantly higher DCR in comparison to stage III patients (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.035). Notably, patients who were aged &#x0003c;&#x02009;60&#x02009;years, with clinical stage IV, co&#x02010;occurring EGFR and TP53 mutations, brain metastases, ECOG PS &#x02264;&#x02009;1, baseline CEA &#x0003c;&#x02009;5&#x02009;&#x003bc;g/L, and a tumor diameter &#x0003e;&#x02009;5&#x02009;mm achieved DCRs of up to 100%. Nevertheless, the significance regarding subgroup results was preliminary due to the limited number of patients and the retrospective nature of this study.</p></sec><sec id="tca70071-sec-0014"><label>3.3</label><title>Survival Outcomes</title><p>The data cutoff date for survival was October 14, 2023. The median follow&#x02010;up of the 28 included patients from the start of anlotinib plus osimertinib was 12.0&#x02009;months (range, 7.8&#x02013;16.2). A total of four (14.3%) patients with gradual progression showed dramatic progression after combination therapy; thus, a combination of anlotinib and osimertinib led to a median PFS1 of 10.0&#x02009;months (95% CI, 8.4&#x02013;11.6&#x02009;months), with an estimated 6&#x02010;month PFS rate of 85.2% (95% CI, 65.2&#x02013;94.2; Figure&#x000a0;<xref rid="tca70071-fig-0003" ref-type="fig">3A</xref>). From initial osimertinib treatment, the 28 patients had a median follow&#x02010;up of 31.5&#x02009;months (range, 20.8&#x02013;42.2). The median PFS2 from first&#x02010;line osimertinib to progression with combination therapy was 22.0&#x02009;months (95% CI, 17.5&#x02013;26.5&#x02009;months; Figure&#x000a0;<xref rid="tca70071-fig-0003" ref-type="fig">3B</xref>). With a relatively short follow&#x02010;up, the median OS has yet to be immature.</p><fig position="float" fig-type="FIGURE" id="tca70071-fig-0003"><label>FIGURE 3</label><caption><p>Kaplan&#x02013;Meier survival curves of progression&#x02010;free survival. (A) Progression&#x02010;free survival after anlotinib plus osimertinib. (B) Progression&#x02010;free survival from first&#x02010;line osimertinib.</p></caption><graphic xlink:href="TCA-16-e70071-g003" position="anchor" id="jats-graphic-7"/></fig><p>After stratifying according to baseline characteristics, the median PFS1 was significantly longer in nonsmokers (11.0&#x02009;months [95% CI, 10.0&#x02013;12.0&#x02009;months]; Figure&#x000a0;<xref rid="tca70071-supitem-0002" ref-type="supplementary-material">S2</xref>) than in smokers (8.0&#x02009;months [95% CI, 5.3&#x02013;10.7&#x02009;months], <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.048). Other analyzed clinical factors showed no significant association with median PFS1 (<italic toggle="yes">p</italic>&#x02009;&#x0003e;&#x02009;0.05; Figure&#x000a0;<xref rid="tca70071-supitem-0002" ref-type="supplementary-material">S2</xref>). For instance, patients with an EGFR L858R mutation (11.0&#x02009;months; 95% CI, 7.9&#x02013;14.2) had a numerically longer PFS than patients with an EGFR T790M mutation (10.0&#x02009;months; 95% CI, 6.5&#x02013;13.5) or an EGFR 19del mutation (9.4&#x02009;months; 95% CI, 5.1&#x02013;13.7), although this was not statistically different (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.569).</p><p>To further identify patients who may benefit more from this combination, patients were categorized into two subgroups according to co&#x02010;occurring mutations: co&#x02010;occurring EGFR and TP53 mutations (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5) vs. co&#x02010;occurring EGFR and other mutations (<italic toggle="yes">n</italic>&#x02009;=&#x02009;8). The mutation type was not associated with either PFS1 (11.0&#x02009;months vs. 10&#x02009;months; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.725; Figure&#x000a0;<xref rid="tca70071-supitem-0003" ref-type="supplementary-material">S3A</xref>) or PFS2 (31.75&#x02009;months vs. 19.2&#x02009;months; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.060; Figure&#x000a0;<xref rid="tca70071-supitem-0003" ref-type="supplementary-material">S3B</xref>) with our combination therapy.</p></sec><sec id="tca70071-sec-0015"><label>3.4</label><title>Safety</title><p>During combination therapy, all patients (100%) experienced treatment&#x02010;related toxicities. The most commonly observed toxic reactions were diarrhea (60.7%), poor appetite (50.0%), nausea (46.4%), hypertension (35.7%), and vomiting (32.1%). Grade 3 toxicities occurred in three patients (10.7%), including diarrhea, nausea, and vomiting (3.6% each; Table&#x000a0;<xref rid="tca70071-tbl-0003" ref-type="table">3</xref>). No patients experienced grade &#x02265;&#x02009;4 toxicities or discontinued treatment due to treatment&#x02010;related toxicities. No dose adjustments were made for any of the patients throughout the treatment course. No treatment&#x02010;related deaths occurred after combination therapy.</p><table-wrap position="float" id="tca70071-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Incidence of TRAEs after anlotinib plus osimertinib therapy in nsq&#x02010;NSCLC patients with gradual progression on osimertinib.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Adverse event</th><th align="center" colspan="3" valign="bottom" rowspan="1">Overall (<italic toggle="yes">n</italic>&#x02009;=&#x02009;28), <italic toggle="yes">n</italic> (%)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">All grades</th><th align="center" valign="bottom" rowspan="1" colspan="1">Grade 1&#x02013;2</th><th align="center" valign="bottom" rowspan="1" colspan="1">Grade 3</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Any events</td><td align="center" valign="top" rowspan="1" colspan="1">28 (100)</td><td align="center" valign="top" rowspan="1" colspan="1">25 (89.3)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (10.7)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Diarrhea</td><td align="center" valign="top" rowspan="1" colspan="1">17 (60.7)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (57.1)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.6)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Poor appetite</td><td align="center" valign="top" rowspan="1" colspan="1">14 (50.0)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (50.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Nausea</td><td align="center" valign="top" rowspan="1" colspan="1">13 (46.4)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (42.8)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.6)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hypertension</td><td align="center" valign="top" rowspan="1" colspan="1">10 (35.7)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (35.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Vomiting</td><td align="center" valign="top" rowspan="1" colspan="1">9 (32.1)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (28.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.6)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">ALT increased</td><td align="center" valign="top" rowspan="1" colspan="1">8 (28.6)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (28.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cough</td><td align="center" valign="top" rowspan="1" colspan="1">8 (28.6)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (28.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Constipation</td><td align="center" valign="top" rowspan="1" colspan="1">8 (28.6)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (28.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Alopecia</td><td align="center" valign="top" rowspan="1" colspan="1">7 (25.0)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (25.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">AST increased</td><td align="center" valign="top" rowspan="1" colspan="1">7 (25.0)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (25.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Weight decreased</td><td align="center" valign="top" rowspan="1" colspan="1">6 (21.4)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (21.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hyponatremia</td><td align="center" valign="top" rowspan="1" colspan="1">5 (17.9)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (17.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Proteinuria</td><td align="center" valign="top" rowspan="1" colspan="1">4 (14.3)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (14.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hypokalemia</td><td align="center" valign="top" rowspan="1" colspan="1">4 (14.3)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (14.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot id="tca70071-ntgp-0004"><fn id="tca70071-note-0006"><p>
<italic toggle="yes">Note:</italic> Data are <italic toggle="yes">n</italic> (%). There were no grade 4&#x02013;5 events.</p></fn><fn id="tca70071-note-0007"><p>Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="tca70071-sec-0016"><label>4</label><title>Discussion</title><p>This study provided evidence of anti&#x02010;angiogenic drugs plus EGFR&#x02010;TKIs in nsq&#x02010;NSCLC with gradual progression when on third&#x02010;generation EGFR&#x02010;TKI osimertinib. The combination of anlotinib plus osimertinib has shown promising efficacy with a median PFS of 10.0&#x02009;months and DCR of 85.7%. Even in patients with brain metastases, the regimen showed an effective tumor response with a DCR of 100%. In addition, the regimen demonstrated a tolerable safety profile with a low incidence of grade &#x02265;&#x02009;3 adverse events (AEs). The results of this study support further validation of this regimen in clinical studies.</p><p>For those patients with nonsquamous nonsmall&#x02010;cell lung cancer (nsq&#x02010;NSCLC) who have disease progression after osimertinib treatment, there are a variety of treatment options currently available. Multiple treatment options exist and are approved including platinum&#x02010;pemetrexed; carboplatin/paclitaxel/atezolizumab/bevacizumab; carboplatin/pemetrexed+Amivantamab and Sintilimab+Bevacizumab+Chemo [<xref rid="tca70071-bib-0027" ref-type="bibr">27</xref>, <xref rid="tca70071-bib-0028" ref-type="bibr">28</xref>]. Among the numerous treatment options after the progression of osimertinib treatment, the combination of osimertinib and anlotinib demonstrates certain advantages. The present study observed that a combination of anlotinib and osimertinib following osimertinib failure yielded an encouraging response (ORR, 3.6%; DCR, 85.7%) and promising survival signal (median PFS1, 10.0&#x02009;months) in patients with nsq&#x02010;NSCLC showing gradual progression when on osimertinib. The survival benefit of the combination regimen in this study was superior to that previously reported with the addition of apatinib (median PFS, 8.2&#x02009;months) [<xref rid="tca70071-bib-0029" ref-type="bibr">29</xref>] or savolitinib (median PFS, 7.6&#x02009;months) [<xref rid="tca70071-bib-0030" ref-type="bibr">30</xref>] after gradual progression with first&#x02010;line EGFR&#x02010;TKIs. Notably, prior studies have reported that switching to combination therapy after progression is more effective than continuing EGFR&#x02010;TKI monotherapy [<xref rid="tca70071-bib-0009" ref-type="bibr">9</xref>]. Encouragingly, our regimen was more effective than previous regimens starting with prior therapy (median PFS, 22.0 vs. 20.9&#x02009;months). The advantage here could potentially be due to the potent synergy between anlotinib and osimertinib, which reverses acquired resistance to osimertinib by targeting the c&#x02010;MET/MYC/AXL axis and downstream MAPK and PI3K/AKT signaling pathways [<xref rid="tca70071-bib-0031" ref-type="bibr">31</xref>]. However, although results appear promising, comparisons across studies should be interpreted with caution as study designs and sample sizes may differ.</p><p>Moreover, several meaningful findings were observed from subgroup analysis. We observed that a combination regimen showed superior anti&#x02010;tumor activity with a DCR of 100% in nsq&#x02010;NSCLC patients with brain metastases in this study, which may be attributed to the active effect of anlotinib in the brain. Anlotinib improved intracranial efficacy in patients with brain metastases and played a potential role in tumor control at intracranial sites [<xref rid="tca70071-bib-0032" ref-type="bibr">32</xref>]. Additionally, a subgroup analysis also demonstrated that our combination is more effective for nonsmokers than for former smokers, similar to that found with anlotinib plus pemetrexed in EGFR/ALK wild&#x02010;type advanced nsq&#x02010;NSCLC [<xref rid="tca70071-bib-0033" ref-type="bibr">33</xref>]. Compared with smokers, nonsmokers have a different genomic makeup and prevalent somatic mutations in EGFR, ERBB2, ALK, and ROS1, which may also contribute to their greater benefit from targeted therapy [<xref rid="tca70071-bib-0034" ref-type="bibr">34</xref>]. This study also found that stage IV patients benefited more from combination therapy compared to stage III patients.</p><p>Identifying populations that are more likely to benefit from biomarkers has great clinical importance. Although no association was found between EGFR L858R, T790M, and 19del and responses, an association between TP53 mutations and PFS was determined. Treatment with EGFR&#x02010;TKI showed worse efficacy in patients with TP53 mutations, as reported in previous studies [<xref rid="tca70071-bib-0035" ref-type="bibr">35</xref>, <xref rid="tca70071-bib-0036" ref-type="bibr">36</xref>]. However, our combination regimen showed similar efficacy in both groups of patients with TP53 and other mutations. Although a statistical difference did not exist, our study revealed that patients with TP53 mutations who demonstrated slow progression on osimertinib and subsequently received combined treatment with osimertinib and anlotinib exhibited a longer PFS compared to patients with other mutations. Patients with TP53 mutations may potentially benefit from combination therapy. However, the sample size of this study is small and needs further verification.</p><p>A combination of anlotinib and osimertinib showed acceptable tolerability in this population. The reported treatment&#x02010;related toxicities were known and common, such as diarrhea, poor appetite, nausea, and hypertension, and were similar to monotherapy regimens with osimertinib or anlotinib [<xref rid="tca70071-bib-0037" ref-type="bibr">37</xref>, <xref rid="tca70071-bib-0038" ref-type="bibr">38</xref>, <xref rid="tca70071-bib-0039" ref-type="bibr">39</xref>], implicating that combination therapy in the present study did not increase risk. Based on the results of the ORCHARD study, in patients who showed an initial resistance to osimertinib and were subsequently put on additional necitumumab combination therapy, up to 44% experienced one or more grade &#x02265;&#x02009;3 AEs, 31% experienced serious AEs, and 13% died [<xref rid="tca70071-bib-0040" ref-type="bibr">40</xref>]. By contrast, only 10.7% of grade 3 AEs were observed in the present study, suggesting that our combination regimen may be safer and acceptable. However, our study was retrospective, which would lead to an underestimation of the incidence of AEs. Additionally, the toxicities of the combination regimen were generally controllable and tolerable since these resolved soon after symptomatic treatment; no one discontinued study treatment because of toxicities. Overall, these findings suggest that combining anlotinib with osimertinib may be a safer treatment option in this population.</p><p>Although important discoveries were revealed by our study, several limitations still exist. First, the relatively small sample size of patients used in this study may lead to a bias in our results. Second, our study had its inherent limitations of having a retrospective and nonrandomized design. Finally, the limited observation period led to a lack of long&#x02010;term efficacy. Thus, further prospective trials are still warranted to validate our findings.</p></sec><sec sec-type="conclusions" id="tca70071-sec-0017"><label>5</label><title>Conclusions</title><p>In conclusion, anlotinib plus osimertinib showed encouraging anti&#x02010;tumor activity and had a manageable safety profile in nsq&#x02010;NSCLC with gradual progression on osimertinib, providing a feasible and well&#x02010;tolerated treatment option for this population. Moreover, the finding may be considered evidence to further understand the application of anlotinib plus osimertinib as treatment for such patients. Further evaluation of this combination regimen needs to be made in larger randomized clinical trials in the future.</p></sec><sec id="tca70071-sec-0018"><title>Author Contributions</title><p>
<bold>Yu Hua:</bold> software, validation, writing &#x02013; review and editing. <bold>Minghui Liu:</bold> software, validation, writing&#x02009;&#x02013;&#x02009;review and editing. <bold>Boshi Li:</bold> software, validation, writing &#x02013; review and editing. <bold>Hongbing Zhang:</bold> data curation, methodology. <bold>Zihe Zhang:</bold> data curation, methodology. <bold>Yanan Wang:</bold> formal analysis, validation. <bold>Jinghao Liu:</bold> data curation, formal analysis. <bold>Xin Li:</bold> data curation, formal analysis. <bold>Yongwen Li:</bold> conceptualization, data curation, formal analysis, funding acquisition, investigation, project administration, resources. <bold>Sen Wei:</bold> investigation, methodology, project administration, resources, supervision, validation, writing &#x02013; review and editing. <bold>Hongyu Liu:</bold> funding acquisition, investigation, methodology, project administration, resources, supervision, validation, writing &#x02013; review and editing. <bold>Jun Chen:</bold> funding acquisition, investigation, methodology, project administration, resources, supervision, validation, writing &#x02013; review and editing.</p></sec><sec id="tca70071-sec-0020"><title>Ethics Statement</title><p>The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was approved by the Ethics Committee of Tianjin Medical University General Hospital (approval number: IRB2023&#x02010;YX&#x02010;324&#x02010;01). It was conducted in compliance with the 1964 Declaration of Helsinki and applicable local laws and regulations. As our study was noninterventional and retrospective, informed consent was waived by the committee or the institutional.</p></sec><sec sec-type="conclusions" id="tca70071-sec-0021"><title>Consent</title><p>The authors have nothing to report.</p></sec><sec sec-type="COI-statement" id="tca70071-sec-0022"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="tca70071-supitem-0001" position="float" content-type="local-data"><caption><p>
<bold>Figure S1.</bold> Univariate analysis of factors influencing disease control rate.</p></caption><media xlink:href="TCA-16-e70071-s001.tif"/></supplementary-material><supplementary-material id="tca70071-supitem-0002" position="float" content-type="local-data"><caption><p>
<bold>Figure S2.</bold> Univariate analysis of factors influencing progression&#x02010;free survival.</p></caption><media xlink:href="TCA-16-e70071-s003.tif"/></supplementary-material><supplementary-material id="tca70071-supitem-0003" position="float" content-type="local-data"><caption><p>
<bold>Figure S3.</bold> Kaplan&#x02013;Meier survival curves of progression&#x02010;free survival with co&#x02010;occurring mutation. (A) Progression&#x02010;free survival after anlotinib plus osimertinib. (B) Progression&#x02010;free survival from first&#x02010;line osimertinib.</p></caption><media xlink:href="TCA-16-e70071-s002.tif"/></supplementary-material></sec></body><back><ack id="tca70071-sec-0019"><title>Acknowledgments</title><p>The authors have nothing to report.</p></ack><sec sec-type="data-availability" id="tca70071-sec-0024"><title>Data Availability Statement</title><p>Data will be available upon reasonable request to the corresponding author.</p></sec><ref-list content-type="cited-references" id="tca70071-bibl-0001"><title>References</title><ref id="tca70071-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="tca70071-cit-0001">
<string-name>
<given-names>W. D.</given-names>
<surname>Travis</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Brambilla</surname>
</string-name>, <string-name>
<given-names>A. G.</given-names>
<surname>Nicholson</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification</article-title>,&#x0201d; <source>Journal of Thoracic Oncology</source>
<volume>10</volume>, no. <issue>9</issue> (<year>2015</year>): <fpage>1243</fpage>&#x02013;<lpage>1260</lpage>, <pub-id pub-id-type="doi">10.1097/JTO.0000000000000630</pub-id>.<pub-id pub-id-type="pmid">26291008</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="tca70071-cit-0002">
<string-name>
<given-names>Z.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>C. M.</given-names>
<surname>Fillmore</surname>
</string-name>, <string-name>
<given-names>P. S.</given-names>
<surname>Hammerman</surname>
</string-name>, <string-name>
<given-names>C. F.</given-names>
<surname>Kim</surname>
</string-name>, and <string-name>
<given-names>K. K.</given-names>
<surname>Wong</surname>
</string-name>, &#x0201c;<article-title>Non&#x02010;Small&#x02010;Cell Lung Cancers: A Heterogeneous Set of Diseases</article-title>,&#x0201d; <source>Nature Reviews. Cancer</source>
<volume>14</volume> (<year>2014</year>): <fpage>535</fpage>&#x02013;<lpage>546</lpage>.<pub-id pub-id-type="pmid">25056707</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="tca70071-cit-0003">
<string-name>
<given-names>T.</given-names>
<surname>Shao</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Zhao</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Liang</surname>
</string-name>, and <string-name>
<given-names>W.</given-names>
<surname>Tang</surname>
</string-name>, &#x0201c;<article-title>A Systematic Review and Network Meta&#x02010;Analysis of First&#x02010;Line Immune Checkpoint Inhibitor Combination Therapies in Patients With Advanced Non&#x02010;Squamous Non&#x02010;Small Cell Lung Cancer</article-title>,&#x0201d; <source>Frontiers in Immunology</source>
<volume>13</volume> (<year>2022</year>): <elocation-id>948597</elocation-id>.<pub-id pub-id-type="pmid">36389713</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="tca70071-cit-0004">
<string-name>
<given-names>L.</given-names>
<surname>Crino</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Weder</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>van Meerbeeck</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Felip</surname>
</string-name>, and <collab collab-type="authors">ESMO Guidelines Working Group</collab>
, &#x0201c;<article-title>Early Stage and Locally Advanced (Non&#x02010;Metastatic) Non&#x02010;Small&#x02010;Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow&#x02010;Up</article-title>,&#x0201d; <source>Annals of Oncology</source>
<volume>21</volume>, no. <issue>S5</issue> (<year>2010</year>): <fpage>v103</fpage>&#x02013;<lpage>v115</lpage>.<pub-id pub-id-type="pmid">20555058</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="tca70071-cit-0005">
<string-name>
<given-names>R. S.</given-names>
<surname>Herbst</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Morgensztern</surname>
</string-name>, and <string-name>
<given-names>C.</given-names>
<surname>Boshoff</surname>
</string-name>, &#x0201c;<article-title>The Biology and Management of Non&#x02010;Small Cell Lung Cancer</article-title>,&#x0201d; <source>Nature</source>
<volume>553</volume> (<year>2018</year>): <fpage>446</fpage>&#x02013;<lpage>454</lpage>.<pub-id pub-id-type="pmid">29364287</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="tca70071-cit-0006">
<string-name>
<given-names>G.</given-names>
<surname>Morad</surname>
</string-name>, <string-name>
<given-names>B. A.</given-names>
<surname>Helmink</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Sharma</surname>
</string-name>, and <string-name>
<given-names>J. A.</given-names>
<surname>Wargo</surname>
</string-name>, &#x0201c;<article-title>Hallmarks of Response, Resistance, and Toxicity to Immune Checkpoint Blockade</article-title>,&#x0201d; <source>Cell</source>
<volume>185</volume> (<year>2022</year>): <fpage>576</fpage>.<pub-id pub-id-type="pmid">35120665</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="tca70071-cit-0007">
<string-name>
<given-names>T. C.</given-names>
<surname>Lam</surname>
</string-name>, <string-name>
<given-names>K. C.</given-names>
<surname>Tsang</surname>
</string-name>, <string-name>
<given-names>H. C.</given-names>
<surname>Choi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Combination Atezolizumab, Bevacizumab, Pemetrexed and Carboplatin for Metastatic EGFR Mutated NSCLC After TKI Failure</article-title>,&#x0201d; <source>Lung Cancer</source>
<volume>159</volume> (<year>2021</year>): <fpage>18</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">34303276</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="tca70071-cit-0008">
<string-name>
<given-names>D. A.</given-names>
<surname>Cross</surname>
</string-name>, <string-name>
<given-names>S. E.</given-names>
<surname>Ashton</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Ghiorghiu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>AZD9291, an Irreversible EGFR TKI, Overcomes T790M&#x02010;Mediated Resistance to EGFR Inhibitors in Lung Cancer</article-title>,&#x0201d; <source>Cancer Discovery</source>
<volume>4</volume>, no. <issue>9</issue> (<year>2014</year>): <fpage>1046</fpage>&#x02013;<lpage>1061</lpage>, <pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-0337</pub-id>.<pub-id pub-id-type="pmid">24893891</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="tca70071-cit-0009">
<string-name>
<given-names>J. C.</given-names>
<surname>Soria</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Ohe</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Vansteenkiste</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Osimertinib in Untreated EGFR&#x02010;Mutated Advanced Non&#x02010;Small&#x02010;Cell Lung Cancer</article-title>,&#x0201d; <source>New England Journal of Medicine</source>
<volume>378</volume>, no. <issue>2</issue> (<year>2018</year>): <fpage>113</fpage>&#x02013;<lpage>125</lpage>, <pub-id pub-id-type="doi">10.1056/NEJMoa1713137</pub-id>.<pub-id pub-id-type="pmid">29151359</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="tca70071-cit-0010">
<string-name>
<given-names>G.</given-names>
<surname>Goss</surname>
</string-name>, <string-name>
<given-names>C. M.</given-names>
<surname>Tsai</surname>
</string-name>, <string-name>
<given-names>F. A.</given-names>
<surname>Shepherd</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Osimertinib for Pretreated EGFR Thr790Met&#x02010;Positive Advanced Non&#x02010;Small&#x02010;Cell Lung Cancer (AURA2): A Multicentre, Open&#x02010;Label, Single&#x02010;Arm, Phase 2 Study</article-title>,&#x0201d; <source>Lancet Oncology</source>
<volume>17</volume> (<year>2016</year>): <fpage>1643</fpage>&#x02013;<lpage>1652</lpage>.<pub-id pub-id-type="pmid">27751847</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="tca70071-cit-0011">
<string-name>
<given-names>K. S.</given-names>
<surname>Thress</surname>
</string-name>, <string-name>
<given-names>C. P.</given-names>
<surname>Paweletz</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Felip</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non&#x02010;Small Cell Lung Cancer Harboring EGFR T790M</article-title>,&#x0201d; <source>Nature Medicine</source>
<volume>21</volume> (<year>2015</year>): <fpage>560</fpage>&#x02013;<lpage>562</lpage>.</mixed-citation></ref><ref id="tca70071-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="tca70071-cit-0012">
<string-name>
<given-names>A.</given-names>
<surname>Nishiyama</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Takeuchi</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Adachi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>MET Amplification Results in Heterogeneous Responses to Osimertinib in EGFR&#x02010;Mutant Lung Cancer Treated With Erlotinib</article-title>,&#x0201d; <source>Cancer Science</source>
<volume>111</volume> (<year>2020</year>): <fpage>3813</fpage>&#x02013;<lpage>3823</lpage>.<pub-id pub-id-type="pmid">32735723</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="tca70071-cit-0013">
<string-name>
<given-names>C. C.</given-names>
<surname>Lin</surname>
</string-name>, <string-name>
<given-names>J. Y.</given-names>
<surname>Shih</surname>
</string-name>, <string-name>
<given-names>C. J.</given-names>
<surname>Yu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Outcomes in Patients With Non&#x02010;Small&#x02010;Cell Lung Cancer and Acquired Thr790Met Mutation Treated With Osimertinib: A Genomic Study</article-title>,&#x0201d; <source>Lancet Respiratory Medicine</source>
<volume>6</volume> (<year>2018</year>): <fpage>107</fpage>&#x02013;<lpage>116</lpage>.<pub-id pub-id-type="pmid">29249325</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="tca70071-cit-0014">
<string-name>
<given-names>D.</given-names>
<surname>Planchard</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Loriot</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Andre</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>EGFR&#x02010;Independent Mechanisms of Acquired Resistance to AZD9291 in EGFR T790M&#x02010;Positive NSCLC Patients</article-title>,&#x0201d; <source>Annals of Oncology</source>
<volume>26</volume> (<year>2015</year>): <fpage>2073</fpage>&#x02013;<lpage>2078</lpage>.<pub-id pub-id-type="pmid">26269204</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="tca70071-cit-0015">
<string-name>
<given-names>P. L.</given-names>
<surname>Su</surname>
</string-name>, <string-name>
<given-names>J. S.</given-names>
<surname>Tsai</surname>
</string-name>, <string-name>
<given-names>S. C.</given-names>
<surname>Yang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Survival Benefit of Osimertinib Combination Therapy in Patients With T790M&#x02010;Positive Non&#x02010;Small&#x02010;Cell Lung Cancer Refractory to Osimertinib Treatment</article-title>,&#x0201d; <source>Lung Cancer</source>
<volume>158</volume> (<year>2021</year>): <fpage>137</fpage>&#x02013;<lpage>145</lpage>.<pub-id pub-id-type="pmid">34214933</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="tca70071-cit-0016">
<string-name>
<given-names>D.</given-names>
<surname>Hanahan</surname>
</string-name> and <string-name>
<given-names>R. A.</given-names>
<surname>Weinberg</surname>
</string-name>, &#x0201c;<article-title>Hallmarks of Cancer: The Next Generation</article-title>,&#x0201d; <source>Cell</source>
<volume>144</volume> (<year>2011</year>): <fpage>646</fpage>&#x02013;<lpage>674</lpage>.<pub-id pub-id-type="pmid">21376230</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="tca70071-cit-0017">
<string-name>
<given-names>R. A.</given-names>
<surname>Soo</surname>
</string-name>, <string-name>
<given-names>J. Y.</given-names>
<surname>Han</surname>
</string-name>, <string-name>
<given-names>U.</given-names>
<surname>Dafni</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>A Randomised Phase II Study of Osimertinib and Bevacizumab Versus Osimertinib Alone as Second&#x02010;Line Targeted Treatment in Advanced NSCLC With Confirmed EGFR and Acquired T790M Mutations: The European Thoracic Oncology Platform (ETOP 10&#x02010;16) BOOSTER Trial</article-title>,&#x0201d; <source>Annals of Oncology</source>
<volume>33</volume> (<year>2022</year>): <fpage>181</fpage>&#x02013;<lpage>192</lpage>.<pub-id pub-id-type="pmid">34839016</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="tca70071-cit-0018">
<string-name>
<given-names>H. A.</given-names>
<surname>Yu</surname>
</string-name>, <string-name>
<given-names>L. G.</given-names>
<surname>Paz&#x02010;Ares</surname>
</string-name>, <string-name>
<given-names>J. C.</given-names>
<surname>Yang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Phase I Study of the Efficacy and Safety of Ramucirumab in Combination With Osimertinib in Advanced T790M&#x02010;Positive EGFR&#x02010;Mutant Non&#x02010;Small Cell Lung Cancer</article-title>,&#x0201d; <source>Clinical Cancer Research</source>
<volume>27</volume>, no. <issue>4</issue> (<year>2021</year>): <fpage>992</fpage>&#x02013;<lpage>1002</lpage>, <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-1690</pub-id>.<pub-id pub-id-type="pmid">33046516</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="tca70071-cit-0019">
<string-name>
<given-names>H.</given-names>
<surname>Akamatsu</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Toi</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Hayashi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M&#x02010;Mutated Non&#x02010;Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor&#x02010;Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial</article-title>,&#x0201d; <source>JAMA Oncology</source>
<volume>7</volume>, no. <issue>3</issue> (<year>2021</year>): <fpage>386</fpage>&#x02013;<lpage>394</lpage>.<pub-id pub-id-type="pmid">33410885</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="tca70071-cit-0020">
<string-name>
<given-names>J. J.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>H. J.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>H. H.</given-names>
<surname>Yan</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Clinical Modes of EGFR Tyrosine Kinase Inhibitor Failure and Subsequent Management in Advanced Non&#x02010;Small Cell Lung Cancer</article-title>,&#x0201d; <source>Lung Cancer</source>
<volume>79</volume> (<year>2013</year>): <fpage>33</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">23079155</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="tca70071-cit-0021">
<string-name>
<given-names>F.</given-names>
<surname>Barron</surname>
</string-name>, <string-name>
<given-names>A. F.</given-names>
<surname>Cardona</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Corrales</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Characteristics of Progression to Tyrosine Kinase Inhibitors Predict Overall Survival in Patients With Advanced Non&#x02010;Small Cell Lung Cancer Harboring an EGFR Mutation</article-title>,&#x0201d; <source>Journal of Thoracic Disease</source>
<volume>10</volume>, no. <issue>4</issue> (<year>2018</year>): <fpage>2166</fpage>&#x02013;<lpage>2178</lpage>, <pub-id pub-id-type="doi">10.21037/jtd.2018.03.106</pub-id>.<pub-id pub-id-type="pmid">29850120</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="tca70071-cit-0022">
<string-name>
<given-names>W.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Shao</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Xu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Efficacy and Safety of Anlotinib With and Without EGFR&#x02010;TKIs or Immunotherapy in the Treatment of Elder Patients With Non&#x02010;Small&#x02010;Cell Lung Cancer: A Retrospective Study</article-title>,&#x0201d; <source>BMC Pulmonary Medicine</source>
<volume>22</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>179</fpage>.<pub-id pub-id-type="pmid">35524294</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="tca70071-cit-0023">
<string-name>
<given-names>Y.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Jiang</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Liang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Low&#x02010;Dose Anlotinib Combined With EGFR&#x02010;TKI Can Be Used as an Alternative for EGFR&#x02010;TKI&#x02010;Resistant Non&#x02010;Small Cell Lung Cancer in Elderly Patients</article-title>,&#x0201d; <source>Oncology Letters</source>
<volume>26</volume> (<year>2023</year>): <fpage>323</fpage>.<pub-id pub-id-type="pmid">37415629</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="tca70071-cit-0024">
<string-name>
<given-names>G.</given-names>
<surname>Shen</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Zheng</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Ren</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Anlotinib: A Novel Multi&#x02010;Targeting Tyrosine Kinase Inhibitor in Clinical Development</article-title>,&#x0201d; <source>Journal of Hematology &#x00026; Oncology</source>
<volume>11</volume> (<year>2018</year>): <fpage>120</fpage>.<pub-id pub-id-type="pmid">30231931</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="tca70071-cit-0025">
<string-name>
<given-names>Q.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Lin</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Chen</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Li</surname>
</string-name>, &#x0201c;<article-title>Successful Treatment of Severe Lung Cancer Caused by Third&#x02010;Generation EGFR&#x02010;TKI Resistance due to EGFR Genotype Conversion With Afatinib Plus Anlotinib</article-title>,&#x0201d; <source>Anti&#x02010;Cancer Drugs</source>
<volume>35</volume> (<year>2024</year>): <fpage>93</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">37449979</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="tca70071-cit-0026">
<string-name>
<given-names>C.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Cao</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Cui</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Concurrent Use of Anlotinib Overcomes Acquired Resistance to EGFR&#x02010;TKI in Patients With Advanced EGFR&#x02010;Mutant Non&#x02010;Small Cell Lung Cancer</article-title>,&#x0201d; <source>Thoracic Cancer</source>
<volume>12</volume> (<year>2021</year>): <fpage>2574</fpage>&#x02013;<lpage>2584</lpage>.<pub-id pub-id-type="pmid">34510760</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="tca70071-cit-0027">
<string-name>
<given-names>K.</given-names>
<surname>Fu</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Xie</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Wang</surname>
</string-name>, and <string-name>
<given-names>L.</given-names>
<surname>Fu</surname>
</string-name>, &#x0201c;<article-title>Therapeutic Strategies for EGFR&#x02010;Mutated Non&#x02010;Small Cell Lung Cancer Patients With Osimertinib Resistance</article-title>,&#x0201d; <source>Journal of Hematology &#x00026; Oncology</source>
<volume>15</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>173</fpage>, <pub-id pub-id-type="doi">10.1186/s13045-022-01391-4</pub-id>.<pub-id pub-id-type="pmid">36482474</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="tca70071-cit-0028">
<string-name>
<given-names>S.</given-names>
<surname>Lu</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Jian</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Sintilimab Plus Bevacizumab Biosimilar IBI305 and Chemotherapy for Patients With EGFR&#x02010;Mutated Non&#x02010;Squamous Non&#x02010;Small&#x02010;Cell Lung Cancer Who Progressed on EGFR Tyrosine&#x02010;Kinase Inhibitor Therapy (ORIENT&#x02010;31): First Interim Results From a Randomised, Double&#x02010;Blind, Multicentre, Phase 3 Trial</article-title>,&#x0201d; <source>Lancet Oncology</source>
<volume>23</volume>, no. <issue>9</issue> (<year>2022</year>): <fpage>1167</fpage>&#x02013;<lpage>1179</lpage>.<pub-id pub-id-type="pmid">35908558</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="tca70071-cit-0029">
<string-name>
<given-names>M.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Zhang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Apatinib Added When NSCLC Patients Get Slow Progression With EGFR&#x02010;TKI: A Prospective, Single&#x02010;Arm Study</article-title>,&#x0201d; <source>Cancer Medicine</source>
<volume>12</volume> (<year>2023</year>): <fpage>21735</fpage>&#x02013;<lpage>21741</lpage>.<pub-id pub-id-type="pmid">38033095</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="tca70071-cit-0030">
<string-name>
<given-names>R. J.</given-names>
<surname>Hartmaier</surname>
</string-name>, <string-name>
<given-names>A. A.</given-names>
<surname>Markovets</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>Ahn</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Osimertinib&#x02009;+&#x02009;Savolitinib to Overcome Acquired MET&#x02010;Mediated Resistance in Epidermal Growth Factor Receptor&#x02010;Mutated, MET&#x02010;Amplified Non&#x02010;Small Cell Lung Cancer: TATTON</article-title>,&#x0201d; <source>Cancer Discovery</source>
<volume>13</volume> (<year>2023</year>): <fpage>98</fpage>&#x02013;<lpage>113</lpage>.<pub-id pub-id-type="pmid">36264123</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="tca70071-cit-0031">
<string-name>
<given-names>T.</given-names>
<surname>Lei</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Zhang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Anlotinib Combined With Osimertinib Reverses Acquired Osimertinib Resistance in NSCLC by Targeting the c&#x02010;MET/MYC/AXL Axis</article-title>,&#x0201d; <source>Pharmacological Research</source>
<volume>188</volume> (<year>2023</year>): <elocation-id>106668</elocation-id>.<pub-id pub-id-type="pmid">36681369</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="tca70071-cit-0032">
<string-name>
<given-names>S.</given-names>
<surname>Jiang</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Liang</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Liu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Impact of Anlotinib on Brain Metastases of Non&#x02010;Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)</article-title>,&#x0201d; <source>Oncologist</source>
<volume>25</volume> (<year>2020</year>): <fpage>e870</fpage>&#x02013;<lpage>e874</lpage>.<pub-id pub-id-type="pmid">32077550</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="tca70071-cit-0033">
<string-name>
<given-names>Z.</given-names>
<surname>He</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Ma</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Efficacy and Safety of Anlotinib Combined With Carboplatin and Pemetrexed as First&#x02010;Line Induction Therapy Followed by Anlotinib Plus Pemetrexed as Maintenance Therapy in EGFR/ALK Wild&#x02010;Type Advanced Non&#x02010;Squamous Non&#x02010;Small Cell Lung Cancer in China: A Multicenter, Single&#x02010;Arm Trial</article-title>,&#x0201d; <source>Translational Lung Cancer Research</source>
<volume>11</volume> (<year>2022</year>): <fpage>1657</fpage>&#x02013;<lpage>1666</lpage>.<pub-id pub-id-type="pmid">36090635</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="tca70071-cit-0034">
<string-name>
<given-names>W.</given-names>
<surname>Luo</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Zeng</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Jin</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Distinct Immune Microenvironment of Lung Adenocarcinoma in Never&#x02010;Smokers From Smokers</article-title>,&#x0201d; <source>Cell Reports Medicine</source>
<volume>4</volume> (<year>2023</year>): <elocation-id>101078</elocation-id>.<pub-id pub-id-type="pmid">37301197</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="tca70071-cit-0035">
<string-name>
<given-names>N. I.</given-names>
<surname>Vokes</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Chambers</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Nguyen</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR&#x02010;Mutant Lung Adenocarcinoma</article-title>,&#x0201d; <source>Journal of Thoracic Oncology</source>
<volume>17</volume> (<year>2022</year>): <fpage>779</fpage>&#x02013;<lpage>792</lpage>.<pub-id pub-id-type="pmid">35331964</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="tca70071-cit-0036">
<string-name>
<given-names>H.</given-names>
<surname>Qian</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Hou</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Zhang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Effects of Concurrent TP53 Mutations on the Efficacy and Prognosis of Targeted Therapy for Advanced EGFR Mutant Lung Adenocarcinoma</article-title>,&#x0201d; <source>Cancer Genetics</source>
<volume>278&#x02013;279</volume> (<year>2023</year>): <fpage>62</fpage>&#x02013;<lpage>70</lpage>.</mixed-citation></ref><ref id="tca70071-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="tca70071-cit-0037">
<string-name>
<given-names>J. C.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>Ahn</surname>
</string-name>, <string-name>
<given-names>D. W.</given-names>
<surname>Kim</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Osimertinib in Pretreated T790M&#x02010;Positive Advanced Non&#x02010;Small&#x02010;Cell Lung Cancer: AURA Study Phase II Extension Component</article-title>,&#x0201d; <source>Journal of Clinical Oncology</source>
<volume>35</volume>, no. <issue>12</issue> (<year>2017</year>): <fpage>1288</fpage>&#x02013;<lpage>1296</lpage>, <pub-id pub-id-type="doi">10.1200/JCO.2016.70.3223</pub-id>.<pub-id pub-id-type="pmid">28221867</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="tca70071-cit-0038">
<string-name>
<given-names>S.</given-names>
<surname>Park</surname>
</string-name>, <string-name>
<given-names>M. H.</given-names>
<surname>Lee</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Seong</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>A Phase II, Multicenter, Two Cohort Study of 160&#x02009;mg Osimertinib in EGFR T790M&#x02010;Positive Non&#x02010;Small&#x02010;Cell Lung Cancer Patients With Brain Metastases or Leptomeningeal Disease Who Progressed on Prior EGFR TKI Therapy</article-title>,&#x0201d; <source>Annals of Oncology</source>
<volume>31</volume> (<year>2020</year>): <fpage>1397</fpage>&#x02013;<lpage>1404</lpage>.<pub-id pub-id-type="pmid">32634610</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="tca70071-cit-0039">
<string-name>
<given-names>Y. Y.</given-names>
<surname>Syed</surname>
</string-name>, &#x0201c;<article-title>Anlotinib: First Global Approval</article-title>,&#x0201d; <source>Drugs</source>
<volume>78</volume> (<year>2018</year>): <fpage>1057</fpage>&#x02013;<lpage>1062</lpage>.<pub-id pub-id-type="pmid">29943374</pub-id>
</mixed-citation></ref><ref id="tca70071-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="tca70071-cit-0040">
<string-name>
<given-names>H. A.</given-names>
<surname>Yu</surname>
</string-name>, <string-name>
<given-names>S. B.</given-names>
<surname>Goldberg</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Le</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Biomarker&#x02010;Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation&#x02010;Positive Advanced/Metastatic Non&#x02010;Small Cell Lung Cancer Whose Disease has Progressed on First&#x02010;Line Osimertinib Therapy (ORCHARD)</article-title>,&#x0201d; <source>Clinical Lung Cancer</source>
<volume>22</volume> (<year>2021</year>): <fpage>601</fpage>&#x02013;<lpage>606</lpage>.<pub-id pub-id-type="pmid">34389237</pub-id>
</mixed-citation></ref></ref-list></back></article>